Patents by Inventor Tatsuki Yokoseki

Tatsuki Yokoseki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibody against FZD10 and use thereof
    Patent number: 11079386
    Abstract: The present invention relates to monoclonal antibodies against FZD10. Furthermore, the present invention provides methods for diagnosing FZD10-related diseases using such an antibody, methods for detecting a FZD10 protein, methods for determining drug efficacy after treatment with FZD10 inhibitors, and methods of screening for subjects in whom treatment with FZD10 inhibitors is highly effective, and provides diagnostic reagents containing such an antibody.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: August 3, 2021
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Yosuke Harada, Tatsuki Yokoseki, Yusuke Nakamura
  • MONOCLONAL ANTIBODY AGAINST FZD10 AND USE THEREOF
    Publication number: 20200174002
    Abstract: The present invention relates to monoclonal antibodies against FZD10. Furthermore, the present invention provides methods for diagnosing FZD10-related diseases using such an antibody, methods for detecting a FZD10 protein, methods for determining drug efficacy after treatment with FZD10 inhibitors, and methods of screening for subjects in whom treatment with FZD10 inhibitors is highly effective, and provides diagnostic reagents containing such an antibody.
    Type: Application
    Filed: October 4, 2017
    Publication date: June 4, 2020
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: YOSUKE HARADA, TATSUKI YOKOSEKI, YUSUKE NAKAMURA
  • Antibodies that specifically bind to abeta oligomers and uses thereof
    Patent number: 9090680
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: July 28, 2015
    Assignees: Immunas Pharma, Inc., National Center for Geriatrics and Gerontology
    Inventors: Etsuro Matsubara, Masao Shibata, Tatsuki Yokoseki
  • Antibodies that specifically bind to A beta oligomers and use thereof
    Patent number: 9090679
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: July 28, 2015
    Assignee: Immunas Pharma, Inc.
    Inventors: Tatsuki Yokoseki, Yasuhide Okamoto, Makoto Umeda, Toshiyuki Ito, Yukiho Imai, Shinobu Fujii, Naofumi Takamatsu
  • Antibodies that specifically bind to A? oligomers and uses thereof
    Patent number: 9085614
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: July 21, 2015
    Assignees: Immunas Pharma, Inc., National Center for Geriatrics and Gerontology
    Inventors: Etsuro Matsubara, Masao Shibata, Tatsuki Yokoseki
  • Antibodies that specifically bind to a beta oligomers and use thereof
    Patent number: 8858949
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: October 14, 2014
    Assignee: Immunas Pharma, Inc.
    Inventors: Tatsuki Yokoseki, Yasuhide Okamoto, Makoto Umeda, Naofumi Takamatsu, Toshiyuki Ito, Yukiho Imai, Shinobu Fujii
  • Antibodies that specifically bind to A beta oligomers and use thereof
    Patent number: 8613924
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the anti-bodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: December 24, 2013
    Assignee: Immunas Pharma, Inc.
    Inventors: Tatsuki Yokoseki, Yasuhide Okamoto, Makoto Umeda, Naofumi Takamatsu, Toshiyuki Ito, Yukiho Imai, Shinobu Fujii
  • Antibodies that specifically bind to A? oligomers and uses thereof
    Patent number: 8378081
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: February 19, 2013
    Assignees: Immunas Pharma, Inc., National Center for Geriatrics and Gerontology
    Inventors: Etsuro Matsubara, Masao Shibata, Tatsuki Yokoseki
  • Antibodies That Specifically Bind to A Beta Oligomers and Use Thereof
    Publication number: 20120177664
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Application
    Filed: August 5, 2010
    Publication date: July 12, 2012
    Applicant: Immunas Pharma, Inc.
    Inventors: Tatsuki Yokoseki, Yasuhide Okamoto, Makoto Umeda, Naofumi Takamatsu, Toshiyuki Ito, Yukiho Imai, Shinobu Fujii
  • Antibodies That Specifically Bind to A Beta Oligomers and Use Thereof
    Publication number: 20120156193
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the anti-bodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Application
    Filed: August 5, 2010
    Publication date: June 21, 2012
    Applicant: IMMUNAS PHARMA, INC.
    Inventors: Tatsuki Yokoseki, Yasuhide Okamoto, Makoto Umeda, Naofumi Takamatsu, Toshiyuki Ito, Yukiho Imai, Shinobu Fujii
  • Antibodies That Specifically Bind to ABeta Oligomers and Uses Thereof
    Publication number: 20120141477
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Application
    Filed: February 9, 2012
    Publication date: June 7, 2012
    Applicants: National Center for Geriatrics and Gerontology, Immunas Pharma, Inc.
    Inventors: Etsuro MATSUBARA, Masao SHIBATA, Tatsuki YOKOSEKI
  • Antibodies That Specifically Bind To A Beta Oligomers And Use Thereof
    Publication number: 20120082667
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Application
    Filed: April 16, 2010
    Publication date: April 5, 2012
    Applicant: IMMUNAS PHARMA, INC.
    Inventors: Tatsuki Yokoseki, Yasuhide Okamoto, Makoto Umeda, Toshiyuki Ito, Yukiho Imai, Shinobu Fujii, Naofumi Takamatsu
  • Antibody Capable of Binding Specifically to AB-Oligomer, and Use Thereof
    Publication number: 20110097319
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Application
    Filed: August 5, 2010
    Publication date: April 28, 2011
    Applicants: Immunas Pharma, Inc., National Center for Geriatrics and Gerontology
    Inventors: Etsuro MATSUBARA, Masao Shibata, Tatsuki Yokoseki
  • Antibody Specific Binding to A-Beta Oligomer and the Use
    Publication number: 20100291071
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Application
    Filed: July 31, 2009
    Publication date: November 18, 2010
    Applicants: Immunas Pharma, Inc., National Center for Geriatrics and Gerontology
    Inventors: Etsuro Matsubara, Masao Shibata, Tatsuki Yokoseki
  • Antibody Specific Binding to A Beta Oligomer and the Use
    Publication number: 20100260783
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Application
    Filed: April 19, 2010
    Publication date: October 14, 2010
    Applicants: Immunas Pharma, Inc., National Center for Geriatrics and Gerontology
    Inventors: Etsuro Matsubara, Masao Shibata, Tatsuki Yokoseki
  • Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof
    Publication number: 20100028357
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Application
    Filed: July 31, 2009
    Publication date: February 4, 2010
    Applicants: Immunas Pharma, Inc., Japan as Represented by President of National Center for Geriatrics and Gerontology
    Inventors: Etsuro Matsubara, Masao Shibata, Tatsuki Yokoseki